The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases

Trial Profile

The RUXexia Trial: An Open-label Phase II Trial of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2016

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Cachexia
  • Focus Therapeutic Use
  • Most Recent Events

    • 24 Feb 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 02 Apr 2015 Planned End Date changed from 1 Apr 2016 to 1 Apr 2018 as reported by ClinicalTrials.gov.
    • 02 Apr 2015 Planned primary completion date changed to 1 Apr 2017 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top